期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 58, 期 3, 页码 1038-1052出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm501092z
关键词
-
资金
- National Cancer Institute (NCI), National Institutes of Health (NIH)
- Prostate Cancer Foundation
- Leukemia and Lymphoma Society
- Ascenta Therapeutics
- Sanofi
Design of small-molecule inhibitors (MDM2 inhibitors) to block the MDM2-p53 protein-protein interaction has been pursued as a new cancer therapeutic strategy. In recent years, potent, selective, and efficacious MDM2 inhibitors have been successfully obtained and seven such compounds have been advanced into early phase clinical trials for the treatment of human cancers. Here, we review the design, synthesis, properties, preclinical, and clinical studies of these clinical-stage MDM2 inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据